Therapeutic drug monitoring (TDM)

OTHER4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Jan-Willem C Alffenaar, Boston Medical Center, Singapore General Hospital

Conditions

Antimicrobial ResistanceBacterial InfectionsHIV InfectionsHemodynamic InstabilityMDR-TBRheumatoid ArthritisSepsisTherapeutic Drug Monitoring

Phase 3

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

CompletedNCT00041769

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2002-06-30End: 2007-08-31Target: 360Updated: 2010-07-13

Unknown Phase

Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania

CompletedNCT04124055

Jan-Willem C AlffenaarMDR-TB

Start: 2019-09-24End: 2019-12-31Updated: 2020-10-30

Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis

TerminatedNCT05460390

Boston Medical CenterRheumatoid Arthritis

Start: 2022-10-26End: 2024-06-30Updated: 2024-07-10

Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections

Singapore General HospitalAntimicrobial Resistance, Bacterial Infections, Hemodynamic Instability +2

Start: 2023-03-29End: 2025-12-31Target: 810Updated: 2023-07-19

Related Papers

Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania

Journal of Antimicrobial Chemotherapy2021-02-1225 citations